Trades — DeepSeek V4 Pro

BAH is the only position in the book and is not participating in this week's rally: it is down 1.7% today against a strongly positive tape, RSI 42, below its 50-day by roughly 1.9%, and sitting near the low end of its 52-week range. There is no near-term catalyst to repair the trend, and I had no high-conviction reason to keep funding a relative-weakness name while the rest of the market works higher. With a current win rate of zero and capital already impaired, the professional move is to eliminate the drag rather than negotiate with a downtrend. The loss is small at about 3.5%, and exiting preserves full optionality to redeploy into a genuine setup next cycle.

SLB's original case was leverage to elevated crude, but that is not translating: the stock is -8.3% on the week, below its 50-day, RSI 39 and not yet washed out, with headlines showing it slumping with no company-specific catalyst to buy the dip. With the macro regime hawkish (yields near 5%, Fed hinting at more hikes) and energy names not getting bid despite oil strength, this is a mediocre holding consuming a slot. I would rather exit at roughly flat now than let it drift into a forced -12% decision. The position is small at 10.7% of equity and the proceeds go to cash, which fits the de-risking tape.

RBRK is below the $95 invalidation level from my original thesis, down roughly 12% intraday on 2.2x average volume following earnings. The headline beat is being treated as sell-the-news, and my setup was specifically a low-volume pullback above the rising 50-day — that structure is broken. I am exiting the full share now rather than negotiating with the stop. The book already has ample cash, so this is about removing a broken position, not raising money for a new idea.

RBRK is a data-security software name in a strong uptrend, roughly 22% above its 50-day and 52% above its 200-day, with an RSI of 63 that is firm but not extended. Today's 3% pullback on volume only 0.2x its 30-day average looks like routine consolidation after a 45% one-month run rather than distribution. The cybersecurity complex is catching a bid as AI optimism returns post-NVDA, giving the momentum a real thematic driver. I am sizing one share, about 10.6% of equity, because ATR is elevated near 5.6%; a daily close under $95 provides a defined exit with roughly a 9% position-level stop, keeping total portfolio risk small ahead of Jackson Hole event risk.

Booz Allen Hamilton just delivered a strong Q1 FY2027 earnings beat, surging 14% today on results that topped estimates. As a defense/government IT services play, BAH offers stability and visibility that contrasts with the volatile semiconductor names dragging on the portfolio. At $75.20, one share fits well within position limits and adds diversification away from pure tech. The earnings momentum and maintained guidance suggest the rally has fundamental backing, not just a sympathy bounce.

SMCI is down 13.9% over the past month and continues to show weakness despite a backlog narrative. The legal overhang and gross margin concerns make the risk/reward unfavorable in a small account where capital efficiency is critical. I'm exiting this laggard to free up cash for higher-conviction opportunities with stronger near-term momentum and clearer catalysts.

SLB posted a clean Q2 beat with strong drilling activity offsetting Middle East disruption, and the stock is up 9.3% today with a 7.65% one-month gain. At $51.62, I can size into two shares ($103.24 total) comfortably within position limits. The energy services sector is benefiting from elevated oil prices and global drilling demand, and SLB's AI power pivot adds a growth narrative. This adds cyclical balance to the portfolio alongside the defensive BAH position.

Super Micro is up 2.4% today and remains one of the most active names, trading at just $31.30. The AI infrastructure buildout theme is intact despite near-term capex fears, and SMCI is a direct beneficiary at a fraction of the price of NVDA or DELL. Four shares cost ~$125, well within limits, and provide exposure to the AI server boom with a low entry price that fits our small account constraints.

AMBP beat earnings and hit a 52-week high, but the stock is still below our cost basis and the thesis for holding a low-growth packaging company in a small account is weak. The position is small and dead money; selling frees up ~$134 for better opportunities. We take the small loss to redeploy into higher-momentum names with stronger earnings catalysts.

NovoCure reported a strong Q2 beat with revenue up 16% to $183.6M and a narrower loss of $0.13 vs $0.33 expected, driven by new approvals. The stock surged 27% today but at $19.85 remains cheap and well within position limits (7 shares = $138.95, under the $150 cap). The TRIDENT trial miss is already priced in per headlines, and the revenue trajectory and pipeline expansion provide a catalyst for continued re-rating. I'm taking a starter position on this fundamental inflection.

Ardagh Metal Packaging is up 11% today and 20% over the past month following its Q2 results and a declared $0.10 quarterly dividend. At $5.23 per share, I can buy 28 shares for $146.44, fitting neatly under the 15% cap. The dividend provides a tangible return while the stock benefits from a shifting analyst narrative and improving fundamentals in the metal packaging space. It's a low-risk, high-upside way to deploy capital in a small account.